Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–108 of 108 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

FARE Peanut SLIT and Early Tolerance Induction

NCT02304991
Conditions
Peanut Hypersensitivity, Food Allergy, Food Hypersensitivity, Peanut Allergy
Interventions
Liquid Peanut Extract, Placebo Glycerin SLIT
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Months to 48 Months
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Dallas, Texas
Completed Phase 3 Interventional Results available

Safety Study of Viaskin Peanut to Treat Peanut Allergy

NCT02916446
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 µg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Completed Phase 3 Interventional Results available

AR101 Real-World Open-Label Extension Study

NCT03337542
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 17 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
55
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Conditions
Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
Interventions
Omalizumab, Dupilumab, Placebo for Dupilumab, Placebo for Omalizumab
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California
Conditions
Peanut Allergy
Interventions
Whole peanut extract, Placebo formulation
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
6 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Willingboro, New Jersey + 2 more
Conditions
Peanut Allergy
Interventions
CNP-201, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
16 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Birmingham, Alabama • Long Beach, California • Mission Viejo, California + 13 more
Conditions
Peanut Allergy
Interventions
Peanut flour
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Food Allergy, Early Allergen Introduction
Interventions
Education and Reminders/Supportive Communication, Education
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
4 Months to 8 Months
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Dallas, Texas
Conditions
Milk and/or Peanut Allergy
Interventions
Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk)
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Early Peanut Introduction: Translation to Clinical Practice

NCT03019328
Conditions
Peanut Allergy
Interventions
Peanut in diet
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
4 Months to 11 Months
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Conditions
Peanut Allergies
Interventions
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose, MY006 Selected Dose, Placebo (Vehicle)
Drug
Lead sponsor
Mabylon AG
Industry
Eligibility
12 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Aurora, Colorado • Colorado Springs, Colorado + 6 more